# First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

> **NCT05768139** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 880 (estimated)

## Conditions studied

- Breast Cancer
- Solid Tumors, Adult

## Interventions

- **DRUG:** STX-478
- **DRUG:** Fulvestrant
- **DRUG:** Ribociclib
- **DRUG:** Palbociclib
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Exemestane
- **DRUG:** Tamoxifen
- **DRUG:** Abemaciclib
- **DRUG:** Imlunestrant
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT05768139
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-17
- **Primary completion:** 2030-07
- **Final completion:** 2030-07
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05768139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05768139, "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05768139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*